Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.35 |
| ▸ | CCR8 | P51685 | 1/20 | 0.35 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20135895 | 0.74 | CCR1 (0.39) | CCR1CCR8KCNJ1CYP1A2 | |
| SCHEMBL29912137 | 0.74 | S100A4 (0.38) | CCR1CCR8 | |
| SCHEMBL9955665 | 0.74 | S100A4 (0.38) | CCR1CCR8 | |
| SCHEMBL17408855 | 0.73 | BCHE (0.37) | KCNJ1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL31336808 | 0.73 | CYP19A1 (0.35) | CCR1CCR8CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL31336815 | 0.73 | NOS3 (0.41) | CCR1CCR8CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL31336616 | 0.71 | TDP1 (0.38) | CYP1A2CYP3A4 | |
| SCHEMBL20113952 | 0.70 | CYP1A2 (0.39) | KCNJ1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL31336812 | 0.68 | ALOX15 (0.42) | — | |
| SCHEMBL31336829 | 0.67 | BRD4 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688154-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | BIAL - Portela & Ca., S.A. (PT) | 2026-02-11 | — | — | EP | disclosed |
| WO-2025023851-A1 | MORPHOLINE OREXIN RECEPTOR ANTAGONISTS | BIAL - PORTELA & CA., S.A. (PT) | 2025-01-30 | — | — | WO | disclosed |